Galapagos is a clinical stage biotech company focused on developing novel medicines.  Headquartered in Belgium, the Company employs over 820 people and reported 2011 revenues of €113 million.

Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.

• Learn more about GLPG0634’s selective JAK1 profile
• View the webcast presentation for GLPG0634
• View the webcast on GLPG0634 deal with Abbott